WO2007047577A3 - Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders - Google Patents
Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders Download PDFInfo
- Publication number
- WO2007047577A3 WO2007047577A3 PCT/US2006/040364 US2006040364W WO2007047577A3 WO 2007047577 A3 WO2007047577 A3 WO 2007047577A3 US 2006040364 W US2006040364 W US 2006040364W WO 2007047577 A3 WO2007047577 A3 WO 2007047577A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cgrp
- antagonists
- sleep
- calcitonin
- breathing disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or more calcitonin gene-related peptide (CGRP) receptor antagonists or release inhibitors. The CGRP receptor antagonist or combination of CGRP receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoid receptor agonists, one or more serotonin reuptake inhibitors, a combination of reuptake inhibitors, other agents, or any combination of the foregoing.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72690005P | 2005-10-14 | 2005-10-14 | |
US60/726,900 | 2005-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007047577A2 WO2007047577A2 (en) | 2007-04-26 |
WO2007047577A3 true WO2007047577A3 (en) | 2007-07-12 |
Family
ID=37866260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/040364 WO2007047577A2 (en) | 2005-10-14 | 2006-10-13 | Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007047577A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420779B2 (en) | 2007-05-22 | 2013-04-16 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2023177823A1 (en) * | 2022-03-17 | 2023-09-21 | Vasoceuticals, Inc. | Combined use of individual compounds for treatment of chronic pain disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080903A1 (en) * | 2001-04-06 | 2002-10-17 | The Board Of Trustees Of The University Of Illinois | Functional role for cannabinoids in autonomic stability during sleep |
US6727242B2 (en) * | 1998-02-27 | 2004-04-27 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
-
2006
- 2006-10-13 WO PCT/US2006/040364 patent/WO2007047577A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727242B2 (en) * | 1998-02-27 | 2004-04-27 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
WO2002080903A1 (en) * | 2001-04-06 | 2002-10-17 | The Board Of Trustees Of The University Of Illinois | Functional role for cannabinoids in autonomic stability during sleep |
Non-Patent Citations (3)
Title |
---|
ARULMANI ET AL: "Calcitonin gene-related peptide and its role in migraine pathophysiology", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 500, no. 1-3, 1 October 2004 (2004-10-01), pages 315 - 330, XP005480426, ISSN: 0014-2999 * |
BAUMAN N M ET AL: "Effect of intravenous calcitonin gene-related peptide antagonist on the laryngeal chemoreflex in piglets.", OTOLARYNGOLOGY--HEAD AND NECK SURGERY : OFFICIAL JOURNAL OF AMERICAN ACADEMY OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY JUL 1999, vol. 121, no. 1, July 1999 (1999-07-01), pages 1 - 6, XP002427117, ISSN: 0194-5998 * |
FRIBERG D ET AL: "Abnormal afferent nerve endings in the soft palatal mucosa of sleep apnoics and habitual snorers", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 71, no. 1, 23 July 1997 (1997-07-23), pages 29 - 36, XP002256079, ISSN: 0167-0115 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007047577A2 (en) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007047372A3 (en) | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists | |
WO2004041183A3 (en) | Methods of treating pulmonary fibrotic disorders | |
CR10627A (en) | THERAPEUTIC METHODS FOR THE TREATMENT OF VASCULAR OCULAR DISORDERS WITH DII4 ANTAGONISTS | |
UA101309C2 (en) | Activin-actrii antagonists thereof and uses for increasing red blood cell levels | |
UA86621C2 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
Ivani et al. | Ketamine: a new look to an old drug. | |
IL207440A (en) | Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of chronic pain and/or symptoms of chronic pain and pharmaceutical compositions and kits comprising the same | |
EA200400982A1 (en) | METHODS OF TREATMENT OF PATIENTS SUFFERING FROM DISTURBANCE OF MOTION | |
MX2010009447A (en) | Use of lhrh antagonists at non-castrating doses. | |
MX2009003469A (en) | Use of hypothermia inducing drugs to treat ischemia. | |
WO2002100352A3 (en) | Nr2b receptor antagonists for the treatment or prevention of migraines | |
WO2006036770A3 (en) | Combination therapy for the treatment of obesity | |
WO2007087457A3 (en) | Combination therapy for the treatment of neovascular disorders | |
MX2009008363A (en) | Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist. | |
WO2004041272A3 (en) | Use of serotonin receptor antagonists for the treatment of sleep apnea | |
ATE507818T1 (en) | ORAL ADMINISTRATION OF A CALCITONIN | |
MX2010000997A (en) | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e). | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
PT1610787E (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases | |
WO2007087557A3 (en) | Surface-layer protein coated microspheres and uses thereof | |
WO2007047577A3 (en) | Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders | |
Tuncer et al. | The pre‐emptive analgesic effect of intra‐articular bupivacaine in arthroscopic knee surgery | |
MXPA05010161A (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases. | |
MX2010012019A (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. | |
EP2323656A4 (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06816991 Country of ref document: EP Kind code of ref document: A2 |